Omar A. Alshaya

733 total citations
27 papers, 352 citations indexed

About

Omar A. Alshaya is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Epidemiology. According to data from OpenAlex, Omar A. Alshaya has authored 27 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cardiology and Cardiovascular Medicine, 8 papers in Internal Medicine and 4 papers in Epidemiology. Recurrent topics in Omar A. Alshaya's work include Atrial Fibrillation Management and Outcomes (8 papers), Venous Thromboembolism Diagnosis and Management (8 papers) and Diabetes Treatment and Management (4 papers). Omar A. Alshaya is often cited by papers focused on Atrial Fibrillation Management and Outcomes (8 papers), Venous Thromboembolism Diagnosis and Management (8 papers) and Diabetes Treatment and Management (4 papers). Omar A. Alshaya collaborates with scholars based in Saudi Arabia and United States. Omar A. Alshaya's co-authors include Abdulrahman Alshaya, Hisham A. Badreldin, Khalid Bin Saleh, Majed S. Al Yami, Mohammed Alrashed, Tariq Alqahtani, Abdulkareem Albekairy, Ishrat Rahman, Sahar S. Alghamdi and Shuroug A. Alowais and has published in prestigious journals such as SHILAP Revista de lepidopterología, Medicine and Journal of Clinical Medicine.

In The Last Decade

Omar A. Alshaya

21 papers receiving 331 citations

Peers

Countries citing papers authored by Omar A. Alshaya

Since Specialization

Citations

This map shows the geographic impact of Omar A. Alshaya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omar A. Alshaya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omar A. Alshaya more than expected).

Fields of papers citing papers by Omar A. Alshaya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Omar A. Alshaya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omar A. Alshaya. The network helps show where Omar A. Alshaya may publish in the future.

Co-authorship network of co-authors of Omar A. Alshaya

This figure shows the co-authorship network connecting the top 25 collaborators of Omar A. Alshaya. A scholar is included among the top collaborators of Omar A. Alshaya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Omar A. Alshaya. Omar A. Alshaya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis 2025 ·Expert Opinion on Drug Safety ·(unknown), (unknown), Sumaya N. Almohareb, Omar A. Alshaya, Abdulaali R. Almutairi	3
2	Frequency, Grades of Toxicity, and Predictors of Hepatotoxicity and Acute Kidney Injury with Remdesivir in COVID-19 Patients: A Multicenter Retrospective Cohort Study 2025 ·Healthcare ·(unknown), Shuroug A. Alowais, (unknown), (unknown), (unknown), (unknown), (unknown), Thamer A. Almangour, Omar A. Alshaya, Khalid Bin Saleh	0
3	Clinical Characteristics and Outcomes of Deep Vein Thrombosis in Relation to Location: A Retrospective Analysis Study 2025 ·Clinical and Applied Thrombosis/Hemostasis ·Majed S. Al Yami, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sumaya N. Almohareb, Omar A. Alshaya, (unknown), Osamah M. Alfayez, Omar A. Almohammed, (unknown)	0
4	Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes 2024 ·Journal of Clinical Medicine ·Sumaya N. Almohareb, Osamah M. Alfayez, (unknown), (unknown), (unknown), Mohammed Kanan Alshammari, Majed S. Al Yami, Omar A. Alshaya, (unknown), Ghazwa B. Korayem, Omar A. Almohammed	6
5	Effectiveness of oral antibiotics in managing extended-spectrum B-lactamase urinary tract infections: A retrospective analysis 2024 ·SAGE Open Medicine ·Sumaya N. Almohareb, Atheer Aldairem, Nada Alsuhebany, Omar A. Alshaya, (unknown), (unknown), (unknown), (unknown), Shuroug A. Alowais	2
6	The prevalence of cardiovascular diseases, chronic kidney disease, and obesity in patients with type 2 diabetes mellitus and the description of concurrent treatments: A two-center retrospective cross-sectional study in Saudi Arabia 2024 ·Saudi Pharmaceutical Journal ·Omar A. Alshaya, Ghazwa B. Korayem, (unknown), (unknown), (unknown), Majed S. Al Yami, Omar A. Almohammed	2
7	Practical Guide for Anticoagulant and Antiplatelet Reversal in Clinical Practice 2023 ·SHILAP Revista de lepidopterología ·(unknown), Hisham A. Badreldin, (unknown), Tariq Alqahtani, Omar A. Alshaya, Majed S. Al Yami, Khalid Bin Saleh, Shmeylan Al Harbi, Abdulrahman Alshaya	14
8	Current developments of ambulatory pharmaceutical care in Saudi Arabia 2023 ·JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY ·(unknown), Omar A. Alshaya, Tahani M. Almeleebia, (unknown), (unknown), Abdulaziz Alqahtani, (unknown), (unknown), (unknown), (unknown), (unknown)	2
9	Real-World Evaluation of the Safety and Effectiveness of Apixaban & Rivaroxaban Lead-in Dosing Compared to Parenteral Lead-in Dosing in the Treatment of Venous Thromboembolism: A Multi-Center Retrospective Cohort Study 2023 ·International Journal of General Medicine ·Ghazwa B. Korayem, Omar A. Alshaya, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Majed S. Al Yami, Omar A. Almohammed	3
10	Clinical characteristics and dosing of apixaban and rivaroxaban for the management of venous thromboembolism: A multi-center retrospective observational study 2023 ·Saudi Pharmaceutical Journal ·Majed S. Al Yami, (unknown), (unknown), (unknown), Ghazwa B. Korayem, Omar A. Alshaya, Omar A. Almohammed	1
11	Chemical versus Mechanical and Chemical Venous Thromboembolism Prophylaxis in Neurocritically Ill Patients: A Cohort Study 2023 ·Clinical Pharmacology Advances and Applications ·Abdulrahman Alshaya, (unknown), (unknown), (unknown), Omar A. Alshaya, Khalid Al Sulaiman, (unknown), (unknown)	0
12	What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies 2022 ·Journal of Cardiovascular Development and Disease ·Hisham A. Badreldin, (unknown), (unknown), (unknown), Nada Yousif, Khalid Al Sulaiman, Ohoud Aljuhani, (unknown), Omar A. Alshaya	5
13	Simulation-Based Education Implementation in Pharmacy Curriculum: A Review of the Current Status 2022 ·Advances in Medical Education and Practice ·Ghazwa B. Korayem, Omar A. Alshaya, (unknown), (unknown), (unknown), (unknown), (unknown)	29
14	Colistin Loading Dose in Septic Patients with Gram Negative Infections 2022 ·Infection and Drug Resistance ·Abdulrahman Alshaya, Khalid Bin Saleh, (unknown), (unknown), (unknown), (unknown), (unknown), Omar A. Alshaya, Khalid Al Sulaiman, (unknown), Shuroug A. Alowais, (unknown), (unknown)	3
15	Calcium Channel Blocker Toxicity: A Practical Approach 2022 ·Journal of Multidisciplinary Healthcare ·Omar A. Alshaya, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mohammed Alrashed, (unknown), Abdulrahman Alshaya	19
16	The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study 2022 ·Frontiers in Public Health ·Ghazwa B. Korayem, Omar A. Alshaya, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Majed S. Al Yami, Omar A. Almohammed	10
17	Thrombolytic therapy in cardiac arrest caused by cardiac etiologies or presumed pulmonary embolism: An updated systematic review and meta‐analysis 2022 ·Research and Practice in Thrombosis and Haemostasis ·Omar A. Alshaya, Abdulrahman Alshaya, Hisham A. Badreldin, (unknown), (unknown), Majed S. Al Yami	5
18	Real-World Effectiveness and Safety of Apixaban versus Warfarin in Patients with Acute Venous Thromboembolism: Experience of a Large Tertiary Hospital in Saudi Arabia 2021 ·International Journal of General Medicine ·Majed S. Al Yami, (unknown), (unknown), Omar A. Alshaya, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ghazwa B. Korayem, Osamah M. Alfayez, Abdulaali R. Almutairi, Omar A. Almohammed	5
19	Safety and effectiveness of thromboprophylaxis use in hospitalized elderly medical patients at a Saudi tertiary care center 2021 ·Saudi Pharmaceutical Journal ·Ghazwa B. Korayem, Omar A. Alshaya, (unknown), (unknown), Omar A. Almohammed, Osamah M. Alfayez, Majed S. Al Yami	0
20	<p>Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation</p> 2020 ·International Journal of General Medicine ·Hisham A. Badreldin, Jahad Alghamdi, Omar A. Alshaya, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact